Yahoo
OTC Markets OTCPK - Delayed Quote USD

Hikma Pharmaceuticals PLC (HKMPY)

43.18 0.00 (0.00%)
At close: September 4 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for HKMPY
  • Previous Close 43.18
  • Open 43.18
  • Bid 42.68 x 110000
  • Ask 44.15 x 100000
  • Day's Range 43.18 - 43.18
  • 52 Week Range 31.80 - 50.56
  • Volume 100
  • Avg. Volume 415
  • Market Cap (intraday) 4.468B
  • Beta (5Y Monthly) 0.66
  • PE Ratio (TTM) 12.27
  • EPS (TTM) 3.52
  • Earnings Date --
  • Forward Dividend & Yield 1.72 (3.98%)
  • Ex-Dividend Date Aug 17, 2026
  • 1y Target Est --

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

www.hikma.com

9,500

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/7/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

HKMPY
8.17%
FTSE 100 (^FTSE)
9.23%

1-Year Return

HKMPY
3.76%
FTSE 100 (^FTSE)
17.81%

3-Year Return

HKMPY
9.29%
FTSE 100 (^FTSE)
45.78%

5-Year Return

HKMPY
29.66%
FTSE 100 (^FTSE)
51.74%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.32%

  • Return on Assets (ttm)

    7.47%

  • Return on Equity (ttm)

    15.41%

  • Revenue (ttm)

    3.42B

  • Net Income Avi to Common (ttm)

    387M

  • Diluted EPS (ttm)

    3.52

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    289M

  • Total Debt/Equity (mrq)

    77.11%

  • Levered Free Cash Flow (ttm)

    14.38M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: